Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017

Authors:

Abstract
Introducing the pneumococcal conjugate vaccine for use among children has been associated with significantly reduced incidence rates of pneumococcal disease, not only among children who were directly targeted for vaccination, but also among older children and adults who were not targeted for vaccination, by preventing the transmission of vaccine-type pneumococci.1 Three years after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced among US children in 2013, the incidence of invasive pneumococcal disease, defined as identification of pneumococcus from a normally sterile site, declined by 58% to 72% among US adults.2 In 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 in series with a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all US adults 65 years or older.3 This recommendation was supported by findings from a large randomized clinical trial in adults 65 years or older in the Netherlands (CAPITA trial) that reported that PCV13 provides protection not only against invasive pneumococcal disease (75% vaccine effectiveness [VE]), but also against vaccine-type noninvasive pneumococcal pneumonia, defined as pneumonia with no identification of pneumococcus from a normally sterile site (45% VE).4 In adults, pneumococcal pneumonia contributes the largest proportion of pneumococcal disease burden. The reported efficacy against the first episode of all-cause community-acquired pneumonia from this trial was 5.1% (95% CI, −5.1 to 14.2). However, continued PCV13 use among children was expected to be associated with further reduced remaining burden of adult pneumococcal disease that was associated with serotypes contained in PCV13 and decrease the effectiveness of PCV13 in preventing pneumococcal disease in adults. Routine PPSV23 use for US adults 65 years or older had been recommended since 1984, but data on PPSV23 effectiveness against noninvasive pneumococcal pneumonia were considered to be inconsistent.3

This publication has 22 references indexed in Scilit: